


Stabilis



Epirubicin hydrochloride



Noms commerciaux

Anthracine	Malaisie
Axirubicine	Allemagne
Bendaepi	Allemagne
Binarin	Mexique
Bioepycina	Pologne
Crisabon	Argentine
Cuatroepi	Argentine
Ecclepia	Roumanie
Elebicin	Mexique
Ellence	Etats Unis d'Amérique
Epi Cell	Allemagne
Epidoxo	Argentine, Chili, Vénézuéla
Epifil	Equateur
Epilem	Colombie, Mexique
Epimedac	Allemagne
Epirubicin	Arabie Saoudite, Australie, Autriche, Belgique, Danemark, Grande Bretagne, Hongrie, Islande, Nouvelle Zélande, Suède, Suisse, Turquie
Epirubicina	Argentine, Colombie, Equateur, Espagne, Mexique, Roumanie
Epirubicine	Belgique, France, Suisse
Farmarubicin	Turquie
Farmorubicin	Arabie Saoudite, Autriche, Brésil, Danemark, Finlande, Grèce, Norvège, Suède, Suisse
Farmorubicin CSV	Afrique du sud
Farmorubicin PFS	Croatie, Pologne, Slovénie
Farmorubicin RD	Brésil, Pologne, Russie, Suisse
Farmorubicin RTU	Pays bas
Farmorubicina	Brésil, Espagne, Italie, Portugal
Farmorubicine	Belgique, France
Pharmorubicin	Grande Bretagne



Stabilité des solutions

		0.1 mg/ml	2-8°C		28			2257

		0.1 mg/ml	25°C		4				2257
		0,05 mg/ml	4°C		25				525
		0.4 mg/ml	2-8°C		4				2257
		0.4 mg/ml	25°C		4				2257
		1 & 2 mg/ml	23°C		150				683
		1 & 2 mg/ml	4°C		150				683
		0,05 mg/ml	4°C		30				525
		1.6 mg/ml	2-8°C		4				2257
		0,04 mg/ml	4°C		7				148
		0,1 mg/ml	-20°C		43				686
		0,1 mg/ml	22°C		8				1897
		0,1 mg/ml	25°C		20				686
		0,1 mg/ml	4°C		43				686
		0,1 mg/ml	4°C		8				1897
		0,2 mg/ml	2-8°C		84				3632
		0,2 mg/ml	25 °C		14				3632
		0.1 mg/ml	2-8°C		28				2257
		0.1 mg/ml	25°C		4				2257
		1 mg/ml	2-8°C		84				3632
		1 mg/ml	25 °C		14				3632
		0,02 mg/ml	22°C		96				1897
		0,05 mg/ml	4°C		25				525
		1 mg/ml	-20°C		28				1237
		1.6 mg/ml	2-8°C		4				2257
		0,05 mg/ml	4°C		30				525
		0.4 mg/ml	2-8°C		4				2257
		0.4 mg/ml	25°C		4				2257
		0,1 mg/ml	22°C		8				1897
		0,1 mg/ml	4°C		8				1897
		0.1 mg/ml	2-8°C		28				2257
		0.1 mg/ml	25°C		4				2257
		0,02 mg/ml	22°C		24				1897
		0,05 mg/ml	4°C		25				525

		0,02 mg/ml	22°C		96			1897
		0,05 mg/ml	4°C		30			525
		0.1 mg/ml	2-8°C		28			2257
		0.1 mg/ml	25°C		4			2257
		2 mg/ml	4°C		43			686
		0,5 mg/ml	20°C		28			1317
		0,5 mg/ml	4°C		28			1317
		1 mg/ml	8°C		84			1823
		1 & 2 mg/ml	23°C		150			683
		1 & 2 mg/ml	4°C		150			683
		2 mg/ml	25°C		14			887
		2 mg/ml	4°C		180			887
		8.33 mg/ml	4°C		72			3473
		2 mg/ml	2-8°C		84			3670



Stabilité en mélange

		0,26 mg/ml	23°C		Palonosetron hydrochloride : 26 µg/ml	4		1955
		25 mg/ml	2-8°C		Iomeprol : 150 mg I/ml	7		3708
		25 mg/ml	2-8°C		Iohexol : 322 mg I/ml	7		3708
		25 mg/ml	2-8°C		Iopromide : 310 mg I/ml	7		3708
		25 mg/ml	2-8°C		Iodixanol : 325 mg I/ml	7		3708
		25 mg/ml	2-8°C		Iohexol : 300 mg I/ml	7		3918
		25 mg/ml	2-8°C		Iomeprol : 300 mg I/ml	7		3918
		25 mg/ml	2-8°C		Iopromide : 300 mg I/ml	7		3918
		25 mg/ml	2-8°C		Iodixanol : 320 mg I/ml	7		3918
		0,0375 mg/ml	25°C		Etoposide : 0,125 mg/ml Vindesine sulfate : 0,002 mg/ml	24		4352
		0,0525 mg/ml	25°C		Vindesine sulfate : 0,0028 mg/ml Etoposide : 0,175 mg/ml	24		4352
		0,075 mg/ml	25°C		Etoposide : 0,250 mg/ml Vindesine sulfate : 0,004 mg/ml	24		4352
		1 mg/ml	4°C		Ifosfamide : 50 mg/ml	28		1317



Facteur influençant la stabilité

	[< 0,5 mg/ml]			1265
	PH >7			3632



Compatibilités

		Epirubicin hydrochloride Fluorouracil		3474
		Epirubicin hydrochloride Heparin sodium		3632
		Epirubicin hydrochloride Irinotecan		2168
		Epirubicin hydrochloride : 0,5 mg/ml Oxaliplatine : 0,5 mg/ml		1662
		Epirubicin hydrochloride : 0,5 mg/ml Palonosetron hydrochloride : 50 µg/ml		1955
		Epirubicin hydrochloride Sodium bicarbonate		3632
		Epirubicin hydrochloride		3632



Voie d'administration



Bibliographie

	Type	Source
148	Revue	Dine T, Cazin JC, Gressier B, Luycks M, Brunet C, Cazin M, Goudaliez F, Mallevais ML, Toraub I. Stability and compatibility of four anthracyclines: doxorubicin, epirubicin, daunorubicin and pirarubicin with PVC infusion bags. Pharm Weekbl [Sci] 1992 ; 14: 365-369.
525	Revue	De Vroe C, De Muyne C, Remon JP, Samsom M. A study on the stability of three antineoplastic drugs and on their sorption by IV delivery systems and end-line filters. Int J Pharm 1990 ; 65: 49-56.
683	Revue	Walker SE, Lau DWC, DeAngelis C, Iazetta J, Coons C. Epirubicin stability in syringes and glass vials and evaluation of chemical contamination. Can J Hosp Pharm 1990 ; 43: 265-272.
686	Revue	Wood MJ, Irwin WJ, Scott DK. Stability of doxorubicin, daunorubicin and epirubicin in plastic syringes and minibags. J Clin Pharm Ther 1990 ; 15: 279-289.

887	Revue	Pujol M, Munoz M, Prat J, Giona V, De Bolos J. Stability study of epirubicin in NaCl 0.9% injection. Ann Pharmacotherapy 1997 ; 31: 992-995.
1237	Revue	Keusters L, Stolk LML, Umans R, Van Asten P. Stability of solutions of doxorubicin and epirubicin in plastic minibags for intravesical use after storage at -20°C and thawing by microwave radiation. Pharm Weekbl [Sci] 1986 ; 8: 194-197.
1265	Revue	Wood MJ, Irwin WJ, Scott DK. Photodegradation of doxorubicin, daunorubicin and epirubicin measured by high-performance liquid chromatography. J Clin Pharm Ther 1990 ; 15: 291-300.
1317	Revue	Adams PS, Haines-Hutt RF, Bradford E, Palmer A, Rowland CG. Pharmaceutical aspects of home infusion therapy for cancer patients. Pharm J 1987 ; 238: 476-478.
1662	Revue	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1823	Revue	Sewell GJ, Rigby-Jones AE, Priston MJ. Stability of intravesical epirubicin infusion: a sequential temperature study. J Clin Pharm Ther 2003 ; 28: 349-353.
1897	Revue	Sautou-Miranda V, Brigas F, Thibault M, Chopineau J. Compatibility of doxorubicin, daunorubicin and epirubicin with low-density polyethylene and polyvinyl chloride, and stability in various conditions of storage. EJHP 2001 ; 7, 3: 108-115.
1955	Revue	Trissel LA, Zhang Y. Palonosetron HCl compatibility and stability with doxorubicin HCl and epirubicin HCl during simulated Y-site administration. Ann Pharmacotherapy 2005 ; 39: 280-283.
2168	Revue	Ozdemir FA, Anilanmert B, Pekin M. Spectrophotometric investigation of the chemical compatibility of the anticancer irinotecan-HCl and epirubicin-HCl in the same infusion solution. Cancer Chemother Pharmacol 2005 ; 56, 5: 529-534.
2257	Laboratoire	Stability of epirubicin "Ebewe" infusion solutions. Ebewe Pharma 2007
3473	Revue	Bennis Y, Savry A, Correard F, Montana M, Sauzet C, Gauthier-Villano L, Pisano P, Pourroy B. Stability of a highly concentrated solution of epirubicin for conventional transcatheter arterial chemoembolization. Int J Pharm 2015 ; 495, 2: 956-962.
3474	Laboratoire	Fluorouracil - Summary of Product Characteristics Accord Healthcare Limited 2009
3632	Laboratoire	Epirubicine (Epirubicine Hospira®) - Summary of Product Characteristics Hospira 2017
3670	Revue	Sewell G, Massimini M. Studies on the stability and compatibility of cytotoxic drug infusion with the Tevadaptor system. EJOP 2014 ; 8, 3: 26-30.
3708	Poster	Sarakbi I, Thiesen J, Krämer I. Compatibility of epirubicin-loaded DC Beads with different contrast media. ECOP 2 Krakow 2014
3918	Revue	Sarakbi I, Krämer I. Compatibility of epirubicin-loaded DC bead™ with different non-ionic contrast media. J Oncol Pharm Practice 2016 ; 22: 749-756.

4352	Revue	Li J, Yao C, Xu Y, Ping P, Yin H, Sun Y. In vitro compatibility and stability of admixtures containing etoposide, epirubicin hydrochloride and vindesine sulphate in a single infusion bag. J Clin Pharm Ther 2019 ; 44: 875-882.
------	-------	---



Dictionnaire

 Anticancéreux	 Injectable
 Noms commerciaux	 Stabilité des solutions
 Contenant	 Molécule
 Concentration	 Température
 Conservation	 Durée de stabilité
 Biosimilaire	 Données conflictuelles
 Bibliographie	 Verre
 NaCl 0,9% ou glucose 5%	 A l'abri de la lumière
 Jour	 Chlorure de sodium 0,9%
 Non précisée	 Glucose 5%
 Polyvinyl chlorure	 Lumière
 Heure	 Polyéthylène
 Polypropylène	 Seringue polypropylène
 Eau pour préparation injectable	 Avec ou sans lumière
 Aucun	 Stabilité en mélange
 Solvant	 Molécule
 DC Beads®	 Polyoléfine
 Facteur influençant la stabilité	 Provoque
 Dégradation	 Compatibilités
 Incompatibilité non précisée	 Incompatible
 Instabilité chimique	 Compatible
 NaHCO ₃	 Voie d'administration
 Intraveineuse	 Intravésicale
 Bibliographie	 Dictionnaire